Subscribe
jarun-ontakrai
Jarun Ontakrai/ Shutterstock.com
14 May 2020Big Pharma

Natera and Illumina settle litigation, agree mutual licence

Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Natera accuses CareDx of infringing DNA testing patents
17 May 2022   Natera has accused rival medical company CareDx of infringing two patents covering its “cell-free” DNA testing technology, Prospera.
Big Pharma
Invitae claims Natera infringed DNA patents
13 May 2021   Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
Americas
Illumina to acquire Jeff Bezos-backed cancer testing company
23 September 2020   Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

More on this story

Big Pharma
Natera accuses CareDx of infringing DNA testing patents
17 May 2022   Natera has accused rival medical company CareDx of infringing two patents covering its “cell-free” DNA testing technology, Prospera.
Big Pharma
Invitae claims Natera infringed DNA patents
13 May 2021   Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
Americas
Illumina to acquire Jeff Bezos-backed cancer testing company
23 September 2020   Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.

More on this story

Big Pharma
Natera accuses CareDx of infringing DNA testing patents
17 May 2022   Natera has accused rival medical company CareDx of infringing two patents covering its “cell-free” DNA testing technology, Prospera.
Big Pharma
Invitae claims Natera infringed DNA patents
13 May 2021   Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
Americas
Illumina to acquire Jeff Bezos-backed cancer testing company
23 September 2020   Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.

More features

GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?
The flaw that landed Sanofi a win in the rare disease space
Roche resolves cancer test dispute with Stanford affiliated startup
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
UK firm expands in Germany with more litigation hires
Sandoz blocked by UK court from seeking Xarelto profits
An update on patenting in Ukraine, Russia and Eurasia